首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1140678

全球腸內營養市場-2022-2029

Global Enteral Feeding Formulas Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

在預測期間（2022-2029 年），腸內營養市場預計將達到 6.8% 的複合年增長率。

腸內餵養是向胃、十二指腸和空腸直接施用含有脂肪、蛋白質、礦物質、碳水化合物、水和維生素的營養完整的飲食。用於輸送腸內營養的管有多種類型，包括胃造口術、鼻空腸管、鼻胃管和空腸瘺管。這些管子由矽膠、聚氨酯或 PVC 製成，長度從 30 到 43 英寸不等，成人的直徑從 8 到 14 英寸不等。用於腸內餵養的其他設備包括劑量容器（瓶子、飼料袋等）、注射器和腸內泵。各種途徑用於管理必要的營養素，但可以選擇具有成本效益、健康和侵入性的過程。因進食障礙（如神經性厭食、吞嚥困難和胃炎）而導致營養不良的患者首選腸內營養。

市場動態

腸內營養的需求猛增，加上腸內營養治療用途的增加和新技術先進腸內營養的引入。此外，全球人口老齡化和早產率上升也在推動市場增長。

慢性病的高患病率推動市場增長

心血管疾病、癌症、糖尿病和（冠狀動脈阻塞性肺病）慢性阻塞性肺病等慢性病患病率的增加預計將推動腸內營養市場的增長。

根據國際糖尿病聯盟的數據，2021 年糖尿病患者將花費 9660 億美元的醫療保健費用，其中 9% 將用於成人。目前，約有 5.37 億成年人（20-79 歲）患有糖尿病，預計到 2045 年將增加到 7.83 億。在大多數國家，2 型糖尿病患者的比例正在增加。大約 5.41 億成年人患 2 型糖尿病的風險增加。據估計，到 2035 年，這種流行率將增加到 45%。根據美國疾病控制和預防中心 (CDC) 的數據，大約一半 (47%) 的美國人口至少有這三個風險因素之一。

治療這些慢性疾病需要更長的住院時間和恢復期。她也有吞嚥食物的問題，所以她通過管子從外部餵食。因此，預計癌症和心血管疾病等慢性疾病的患病率將在預測期內推動市場增長。

醫療報銷不足阻礙腸內營養市場增長

預計腸內營養報銷不足將阻礙腸內營養的使用，並降低預測期內腸內營養的採用率。

市場細分。

全球腸內營養市場根據產品、流程類型、階段、應用和最終用戶進行細分。

腫瘤學有望在腸內營養市場佔據較大市場份額

全世界的癌症負擔正在迅速增加。預計癌症將在預測期內迅速增長。世界衛生組織報告稱，癌症是全球第二大死因，2020 年全球造成 1000 萬人死亡，即六分之一的死亡。大約 70% 的癌症死亡發生在低收入和中等收入國家。據世界衛生組織統計，每年約有 1790 萬人死於心血管疾病，佔全球死亡人數的 32%。大多數患有癌症的患者患有癌症惡病質，這會導致胰島素抵抗、脂肪分解增加、體脂減少、蛋白質周轉增加、肌肉質量下降、食慾下降和體重下降。

此外，接受癌症治療的患者還會因唾液量的變化而出現咀嚼和吞嚥固體食物困難、口腔粘膜炎、吞嚥困難等並發症和副作用。為了改善此類患者的臨床狀況，對經口攝入困難的癌症患者進行腸內營養管餵養，以幫助他們保持體質。

在預測期內，標準製劑市場預計將佔最大份額

按產品分為標準產品和針對疾病的配方。其中，由於對腸內營養和基礎臨床營養的高需求、商業可用性以及大公司不斷增加的投資，標準產品細分市場份額最大。標準配方領域進一步分為聚合物配方和單體配方。隨著對低成本營養補充劑的需求不斷增長，市場上出現了各種各樣的標準化配方。對容量敏感的患者以及患有充血性心力衰竭、SIADH（利尿激素不適當綜合徵）和腎衰竭的患者對標準管飼的需求更高。

同時，由於腸內營養和設備的改進以及幾種慢性病患病率的上升，在 2020-2027 年的預測期內，針對特定疾病的處方將增長最快。特定疾病配方領域進一步細分為腎臟、糖尿病、肝臟、肺和其他。醫療保健專業人員和患者對腸內營養益處的認識不斷提高是推動這一細分市場增長的關鍵因素之一。

分階段來看，2019年成人細分市場份額最大

根據階段，市場分為成人和兒童。由於成年人越來越多地採用管飼法，成人部分在 2019 年佔據了最大的市場份額。對於成人，可以通過注射器法、重力滴注法或泵法進行腸內餵養。Medical Nutrition International Industry 的一項研究表明，歐盟與營養不良或營養不良相關的財務成本約為 1850 億美元。世界上約有六分之一的人受到營養不良的影響。成年人對營養配方奶粉的需求不斷增長是推動該細分市場增長的主要因素之一。

另一方面，由於早產兒增加和住院兒童營養不良患病率上升，預計兒科部門在預測期內將顯著增長。例如，根據聯合國兒童基金會、世界衛生組織和世界銀行發布的一份報告，到 2020 年，超過五分之一的兒童，即約 1.492 億兒童將發育遲緩。胃腸功能障礙的兒科患者因為不能口服營養，所以必須給予腸內營養。一些患有嚴重胃食管反流、過敏、食物排斥行為和代謝紊亂等胃腸道疾病的兒科患者也採用管飼法。

從最終用戶來看，家庭護理預計在預測期內將顯著增長。

由於營養平衡意識的提高和接受家庭腸內營養的患者人數增加，家庭醫療保健預計將在預測期內以最快的速度增長。家庭保健患者中腸內營養的採用正在增加。與國家臨床卓越研究所 (NICE) 合作制定的政策，旨在徹底改變醫療保健服務並加強為使用營養補充劑的患者提供的服務。

按地理

北美在全球腸內營養市場佔有最大份額

由於老年人口不斷增加、早產患病率上升、慢性病患病率上升等因素，北美地區將在 2021 年佔據全球腸內營養市場的最大市場份額。美國是腸內營養市場增長的主要貢獻者。到 2060 年，美國 65 歲及以上的人口數量預計將增加一倍以上。預計人口老齡化將增加癌症和糖尿病等慢性病的數量，導致患者住院時間延長。據世界衛生組織稱，大約有 1500 萬嬰兒早產，而且這個數字還在上升。因此，預計在預測期內，該地區的市場將進一步增長。

亞太地區在預測期內以最快的複合年增長率增長。

預計亞太市場在預測期內將以最快的複合年增長率增長。日本、中國和印度的市場是由大量慢性病和殘疾患者、早產增加、醫療成本上升、醫療基礎設施的快速發展以及這些國家的需求增加所驅動的。預計在預測期內將顯著增長。

競爭格局。

腸內營養市場是一個競爭激烈的市場，既有國內的，也有全球的。為市場增長做出貢獻的主要公司包括 Abbott Laboratories、Fresenius Kabi AG、B. Braun Melsungen AG 和 Steelcase。Braun Melsungen AG、Victus, Inc、Hormel Food Corp、Danone SA、Nestle SA、Mead Johnson Nutrition Company、Global Health Products, Inc、Meiji Holdings Co., Ltd.、Trovita Health Science 等。

B. Braun Melsungen AG

概述

B. Brown 主要在醫療技術、醫療服務和製藥領域製造、營銷和分銷一系列醫療保健產品和服務。該公司的產品陣容涵蓋大約 5,000 種產品，其中 95% 是內部製造的。主要產品包括用於輸液、營養和疼痛治療的一次性用品、輸液泵和系統、手術器械、縫合材料、髖關節和膝關節植入物、透析設備和配件、造口和傷口護理產品。B.Brown 在 64 個國家/地區開展業務，並在醫療保健行業的 18 個治療領域開發產品。它通過五個業務部門運營：醫院護理、Aesculap、B. Braun Avitum、門診市場 (OPM) 和其他銷售部門。

產品介紹

腸內營養泵

Enteroport(R) plus：腸內營養泵

用於腸內營養泵“Enterport(R) Plus”的附件 Enterport(R) Plus

飼管

Nutritab(R)：聚氨酯進料管

胃造口管。用於鼻胃管和鼻腸管的 PVC 管，僅供短期使用。

十二指腸管。pvc管

其他

重大發展

領先企業正在採取多種增長戰略，例如產品發布、收購和合作夥伴關係，這有助於全球腸內營養市場的增長。例如：

2020 年 6 月，Hormel Foods被 3BL Media 評為“100 家最佳企業公民”之一，表彰其在美國 1000 家最大的上市公司中出色的環境、社會和治理 (ESG) 透明度和業績增長。這增加了公司的信譽並在市場上建立了知名度

2022 年 4 月 29 日，Fresenius Kabi推出了一款新的腸內營養產品應用程序。該應用程序適用於英國和愛爾蘭共和國的醫護人員。

COVID-19 影響分析

隨著醫院中 COVID-19 病例的增加，對腸內配方的需求也在增加。2020 年，由於 COVID-19 患者的增加，腸內營養行業在重症監護領域出現了繁榮，導致通氣患者的營養補充劑消費量增加。

提高醫護人員對醫院相關營養不良的認識預計將增加醫院腸內營養的使用。此外，在 COVID-19 期間 ICU 入院人數增加，危重患者對腸內營養的需求增加可能會推動市場增長。

Market Overview

Enteral Feeding Formulas Market is expected to reach at a CAGR of 6.8% during the forecast period (2022-2029).

Enteral feeding is the delivery of a nutritionally complete feed containing fat, protein, minerals, carbohydrate, water, and vitamins, directly to the stomach, duodenum, or jejunum. There are various types of tubes available for enteral feed formulae, such as gastrostomy, nasojejunal tube, nasogastric tube, and jejunostomy. These tubes are made of silicone, polyurethane, or PVC and are of different lengths from 30 to 43 inches, with diameters from 8 to 14 inches for adults. Some of the other equipment used for enteral feeding include an administration reservoir (bottle, feed bag, etc.), syringes, and enteral pump. Various routes are used in the administration of the necessary nutrients are cost-effective, healthy, and also a choice for the invasive process. Enteral feeding is preferred for patients with malnutrition due to eating disorders such as anorexia nervosa, dysphagia, and stomach infections, among others.

Market Dynamics

The demand for enteral feeding formula demand is surging with rising therapeutic uses of enteral feeding formula coupled with the introduction of new technologically advanced enteral feeding formula. In addition, the growing geriatric population globally and the rising prevalence of preterm births are also boosting the market growth.

The high prevalence rate of chronic disorders is driving the market growth

Increasing incidences of chronic disorders, such as cardiovascular diseases, cancer, diabetes, and (Coronary Obstructive Pulmonary Disorders) COPD are expected to drive the growth of the enteral feeding formulas market.

As per the International Diabetes Federation, diabetes patients spent US$ 966 billion in health expenditure in 2021, of which, 9 percent of total spending on adults. Around 537 million adults (20-79 years) are living with diabetes currently, and by 2045 this is projected to rise to 783 million. The proportion of type 2 diabetes people is increasing in most countries. Around 541 million adults' people are at increased risk of developing type 2 diabetes. population was suffering from some form of cardiac disease; it is further estimated that this prevalence is likely to increase to 45% by 2035. According to the Centers for Disease Control and Prevention (CDC) of the U.S., about half of the population (47%) of the United States have at least one of these three risk factors.

For the treatment of these chronic diseases, a longer hospital stays and recovery time is required. Patients face problems in swallowing food, so, external nutrition is given to the patient through the tube. Hence, the increase in the cases of chronic diseases, such as cancer and cardiovascular diseases, is expected to drive the growth of the market over the forecast period.

Lack of reimbursement is hampering the growth of the enteral feeding formulas market

The lack of reimbursement of enteral feeding formula is expected to hamper the usage of enteral feeding formula and lower the adoption rate of the enteral feeding formula in the forecast period.

Market Segmentation:

The global enteral feeding formulas market is segmented based on product, flow type, stage, application, and end-users.

The oncology segment is expected to hold a major market share in the enteral feeding formulas market

The burden of cancer is growing rapidly worldwide. Cancer is expected to grow rapidly during the forecast period. The WHO has reported that cancer is the second leading cause of death globally and is responsible for 10 million deaths or one death in 6 deaths in 2020 and worldwide. Also, around 70% of deaths from cancer occur in low and middle-income countries. WHO stated that around 17.9 million people die every year with cardiovascular diseases, and globally, it accounts for 32% of deaths. The majority of tumor-bearing patients suffer from cancer cachexia, which causes insulin resistance, increased lipolysis with loss of body fat, increased protein turnover, and loss of muscle mass, causing loss of appetite and weight.

Also, there are several complications and side effects in the patients while cancer treatment, including difficulty in chewing and swallowing solid food, mucositis sores in the mouth, altered saliva level, which makes it difficult to swallow. To improve the clinical condition of patients, delivery of nutrition is very difficult for the cancer patients to take the food orally, hence, the nutrition is supplied by enteral feeding tubes to help them maintain the body mass.

The standard formulas segment is expected to hold the largest market share during the forecast period

By product, the market is classified into standard and disease-specific formulas. Among these, the standard formulas segment accounted for the largest market share due to its high demand for enteral nutrition and basic clinical nutrition, high commercial availability, and growing investment by major companies. The standard formulas segment is further segmented into polymeric formulas and monomeric formulas. There are different varieties of standard formulas available with the growing demand for low-cost nutrient formulations. The demand for standard tube feeds is high among volume-sensitive patients or patients with congestive heart failure, Syndrome of Inappropriate Diuretic Hormone (SIADH), and renal failure.

On the other hand, the disease-specific formulas are expected to grow at the fastest growth rate during the forecast period, 2020 to 2027 due to growing improvements in enteral feeding formula and devices with the rising prevalence of several chronic diseases. The disease-specific formulas segment is further segmented into renal, diabetic, hepatic, pulmonary, and others. Growing awareness among healthcare professionals and the patient population towards the benefits of enteral medical foods is one of the major factors driving the segment growth.

By Stage, the Adult Segment held the largest market share in 2019

Based on stage, the market is segmented into adults and pediatrics. The adult segment accounted for the largest market share in 2019, due to the growing adoption of tube feed among adults. The enteral feeding can be performed by the syringe method, gravity drip method, and pump method in adults. According to a study by the Medical Nutrition International Industry, the financial cost associated with malnutrition or undernutrition in the European Union is around US$ 185 billion. About one in six individuals are affected by malnutrition globally. The growing demand for such nutrition formulations in the adult population is one of the major factors boosting segment growth.

On the other hand, the pediatrics segment is expected to grow significantly over the forecast period, due to the rising number of premature births and increasing prevalence rate of malnutrition among hospitalized children. For instance, as per the report published by UNICEF-WHO-World Bank, more than one in five that is around 149.2 million children were stunted in 2020. Pediatric patients with a dysfunctional gastrointestinal tract cannot ingest nutrients orally and thus administer enteral feeding. Some pediatric patients suffering from gastrointestinal disorders, such as severe gastroesophageal reflux, allergies, food refusal behavior, and metabolic disorders are also provided tube feeding.

By End-user, Home care is expected to grow significantly over the forecast period.

Home care is expected to grow at the fastest growth rate over the forecast period, owing to the rising number of patients receiving home enteral feeding with growing awareness towards balanced nutrition. There is a rise in the adoption of enteral feeding formulas among home healthcare patients. A policy was developed in combination with the National Institute for Clinical Excellence (NICE) which has revolutionized the healthcare service for patients on nutrition supplements and has enhanced the service delivery. Geographical Presentation:

North America region holds the largest market share in the global enteral feeding formulas market

North America region is dominating the global enteral feeding formulas market accounted for the largest market share in 2021, due to several factors, such as the growing geriatric population, rising prevalence of preterm birth, and the increasing number of chronic disease patients. The United States is the major contributor to the growth of the enteral feeding formulas market. In the U.S., it is projected that the number of people aged above 65 years will more than double by 2060. The growing geriatric population would increase the cases of chronic diseases, such as cancer and diabetes, which will lead to an increase in the hospital stay of the patient. Also, according to the WHO, around 15 million babies are born preterm, and this number is rising. Hence, the market is expected to grow further in this region over the forecast period.

Asia-Pacific region is growing at the fastest CAGR during the forecast period.

The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period. The market in Japan, China, and India is likely to grow significantly during the forecast period, due to the large presence of patients suffering from chronic diseases and disorders, increasing incidences of preterm births, growing healthcare expenditure, rapidly developing healthcare infrastructure, and growing demand in these countries.

Competitive Landscape:

The enteral feeding formulas market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Fresenius Kabi AG, B. Braun Melsungen AG, Victus, Inc., Hormel Food Corp., Danone S.A., Nestle S.A., Mead Johnson Nutrition Company, Global Health Products, Inc., Meiji Holdings Co., Ltd., Trovita Health Science, among others.

B. Braun Melsungen AG

Overview:

B. Braun is majorly involved in the manufacturing, marketing, and distributing of various healthcare products and services in the fields of medical technology, medical services, and pharmaceutical products. The company's product range comprises around 5,000 products of which 95% of the products are manufactured by the company. Some of the major product lines manufactured by the company include disposables required for infusion, nutrition and pain therapy, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, and stoma and wound care products. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry. The company operates its business through five business divisions which include hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM), and other sales.

Product Portfolio:

Enteral Nutrition Pumps:

Enteroport® plus: Enteral nutrition pump

Accessories Enteroport® plus: Accessories for the enteral nutrition pump Enterport® plus

Feeding Tubes

Nutritub®: Polyurethane feeding tube

Gastric Tubes: Nasogastric and naso-intestinal PVC tubes for short-term use only.

Duodenal Tubes: PVC tube

Others

Key Development:

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Enteral Feeding Formulas market globally. For instance,

In June 2020, Hormel Foods has been named to the 100 Best Corporate Citizens list by 3BL Media, recognizing outstanding environmental, social, and governance (ESG) transparency and performance among the 1,000 largest U.S. public companies. This increases the credibility of the company and establishes a good name in the market

On 29th April 2022, Fresenius Kabi launched its new Enteral nutrition product app. That app is available for healthcare professionals in the United Kingdom and the Republic of Ireland.

COVID-19 Impact Analysis

The demand for enteral feeding formulas is growing with the increasing number of COVID-19 cases in hospitals. In 2020, the critical care segment is rapidly growing in the enteral feeding formula industry due to the rising number of COVID-19 patients, which are also leading to the consumption of nutritional feeding formulas more towards the patients with ventilators.

Growing awareness among healthcare professionals regarding hospital-associated malnutrition is anticipated to boost the usage rate of enteral feeding formulas in hospitals. Moreover, the increasing number of ICU admissions during COVID-19, rising demand for enteral formulations among critically ill patients, are likely to boost the market growth.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product
3.2. Market Snippet by Stage
3.3. Market Snippet by Flow Type
3.4. Market Snippet by Application
3.5. Market Snippet by End-User
3.6. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
4.2. Drivers
- 4.2.1. Rising prevalence of chronic diseases and disorders
- 4.2.2. Growing number of preterm births
- 4.2.3. Technological advancement in feeding formulas
- 4.2.4. XX
4.3. Restraints
- 4.3.1. Complications associated with enteral feeding
- 4.3.2. XX
4.4. Opportunity
4.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Unmet Needs

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
- 7.1.2. Market Attractiveness Index, By Product Segment
7.2. Disease-specific Formulas*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.2.3. Pulmonary Formulas
- 7.2.4. Diabetic Formulas
- 7.2.5. Hepatic Formulas
- 7.2.6. Renal Formulas
- 7.2.7. Others
7.3. Standard Formulas
- 7.3.1. Monomeric Formulas
- 7.3.2. Polymeric Formulas

8. By Stage

8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 8.1.2. Market Attractiveness Index, By Stage Segment
8.2. Adults *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3. Pediatrics

9. By Flow Type

9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 9.1.2. Market Attractiveness Index, By Flow Type Segment
9.2. Intermittent Feeding Flow*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
9.3. Continuous Feeding Flow

10. By Application

10.1. Introduction
- 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
- 10.1.2. Market Attractiveness Index, By Application Segment
10.2. Oncology*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
10.3. Diabetes
10.4. Neurology
10.5. Gastroenterology
10.6. Critical Care
10.7. Others

11. By End-User

11.1. Introduction
- 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
- 11.1.2. Market Attractiveness Index, By End-User Segment
11.2. Hospitals*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
11.3. Homecare Agencies & Hospices
11.4. Long-term Care Facilities
11.5. Nursing Homes
11.6. Others

12. By Region

12.1. Introduction
12.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
12.3. Market Attractiveness Index, By Region
12.4. North America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.4.8.1. U.S.
  - 12.4.8.2. Canada
  - 12.4.8.3. Mexico
12.5. Europe
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.5.8.1. Germany
  - 12.5.8.2. U.K.
  - 12.5.8.3. France
  - 12.5.8.4. Italy
  - 12.5.8.5. Spain
  - 12.5.8.6. Rest of Europe
12.6. South America
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.6.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.6.8.1. Brazil
  - 12.6.8.2. Argentina
  - 12.6.8.3. Rest of South America
12.7. Asia Pacific
- 12.7.1. Introduction
- 12.7.2. Key Region-Specific Dynamics
- 12.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
- 12.7.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 12.7.8.1. China
  - 12.7.8.2. India
  - 12.7.8.3. Japan
  - 12.7.8.4. Australia
  - 12.7.8.5. Rest of Asia Pacific
12.8. Middle East and Africa
- 12.8.1. Introduction
- 12.8.2. Key Region-Specific Dynamics
- 12.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 12.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Flow Type
- 12.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Stage
- 12.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 12.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis

14. Company Profiles

14.1. Abbott Laboratories*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Key Highlights
- 14.1.4. Financial Overview
14.2. Fresenius Kabi AG
14.3. B. Braun Melsungen AG
14.4. Victus, Inc.
14.5. Danone S.A.
14.6. Nestle S.A.
14.7. Mead Johnson Nutrition Company
14.8. Health Products, Inc.
14.9. Meiji Holdings Co., Ltd.,
14.10. Trovita Health Science (List Not Exhaustive)